Taiho Pharmaceutical Company Limited

Osaka Bioscience Institute

Riken Corporation

National Center of Neurology and Psychiatry

University of Tsukuba

Kosuke Aritake

Yoshihiro Urade

Naomi Eguchi

Shin'ichi Takeda

Hiroshi Takenaka

Masashi Miyano

Masako Taniike

Ikuko Mori

Yo Sato

Ryo Kawata

Sawako Hyo

Akinori Nakamura

Shinya Kamauchi

Toshihiko Maruyama

SHIN'ICHI Takeda

Sawako 128 Takatsuji-Omiya-Cho Hyo

Yoshihiro 503 Granshitio-Shimogamo-Shikisaikan Urade

Muscle degenerative diseases can be detected in the early stage and the therapeutic efficacy of a therapeutic agent and/or a therapy method for the diseases can be determined by measuring 11,15-dioxo-9&#x3b1;-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid (referred to as 'Tetranor-PGDM', hereinbelow) in a sample isolated from a subject.

Method for detecting muscle degenerative diseases, and method for determining therapeutic efficacy on the diseases

A method is provided for diagnosis of the severity of a condition in an eosinophilic inflammatory disease such as nasal polyp and for prediction of the recurrence of the disease.

Method for diagnosis of severity and prediction of recurrence in eosinophilic inflammatory disease

An object of the present invention is to provide a method which is able to prevent or improve the progress of myolytic diseases such as muscular dystrophy. Such an object is able to be solved by a method where an effective dose of an inhibitor for hematopoietic prostaglandin D synthase (H-PGDS) or an antagonist to prostaglandin D receptor is administered to a patient who needs it. The present invention also provides a method for screening compounds which are able to prevent the progress of myolytic diseases and to improve it using human H-PGDS overexpressed transgenic mice.

Method for treating myolytic disease and method for screening antimyolytic agent

Growing community of inventors

Kawanishi, Japan

Kosuke Aritake